| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Urinary Bladder Neoplasms | 11 | 2019 | 614 | 3.93 | Why? |
| Prostatic Hyperplasia | 5 | 2018 | 161 | 1.55 | Why? |
| Carcinoma, Renal Cell | 4 | 2019 | 545 | 1.47 | Why? |
| Neoplasm Proteins | 3 | 2018 | 501 | 1.43 | Why? |
| Biomarkers, Tumor | 7 | 2019 | 1314 | 1.40 | Why? |
| PPAR gamma | 2 | 2019 | 102 | 1.39 | Why? |
| Cell Cycle | 2 | 2019 | 329 | 1.34 | Why? |
| Sirtuin 1 | 2 | 2017 | 100 | 1.29 | Why? |
| Cell Movement | 3 | 2019 | 695 | 1.13 | Why? |
| Prostatic Neoplasms | 7 | 2018 | 1637 | 1.06 | Why? |
| Kidney Neoplasms | 4 | 2019 | 832 | 0.99 | Why? |
| Renal Insufficiency | 2 | 2020 | 810 | 0.97 | Why? |
| Ethanol | 2 | 2018 | 533 | 0.97 | Why? |
| Gene Expression Profiling | 6 | 2018 | 3788 | 0.89 | Why? |
| Genes, cdc | 1 | 2019 | 9 | 0.80 | Why? |
| Diagnostic Techniques, Respiratory System | 1 | 2020 | 114 | 0.78 | Why? |
| Scrotum | 2 | 2018 | 48 | 0.78 | Why? |
| Goldenhar Syndrome | 1 | 2018 | 3 | 0.78 | Why? |
| Mandibular Osteotomy | 1 | 2018 | 6 | 0.78 | Why? |
| RNA, Neoplasm | 1 | 2019 | 34 | 0.78 | Why? |
| GTPase-Activating Proteins | 1 | 2019 | 36 | 0.77 | Why? |
| Osteogenesis, Distraction | 1 | 2018 | 14 | 0.77 | Why? |
| Estrogen Receptor alpha | 1 | 2019 | 40 | 0.76 | Why? |
| Acid Anhydride Hydrolases | 1 | 2018 | 16 | 0.76 | Why? |
| Collagen Type V | 1 | 2018 | 13 | 0.75 | Why? |
| Receptor, Insulin | 1 | 2018 | 18 | 0.74 | Why? |
| Testicular Diseases | 1 | 2018 | 35 | 0.74 | Why? |
| Mitochondrial Proton-Translocating ATPases | 1 | 2017 | 11 | 0.73 | Why? |
| Mandible | 1 | 2018 | 72 | 0.72 | Why? |
| Fascia | 1 | 2017 | 11 | 0.72 | Why? |
| Forkhead Box Protein O3 | 1 | 2017 | 30 | 0.71 | Why? |
| Computer-Aided Design | 1 | 2018 | 94 | 0.71 | Why? |
| Catheters | 1 | 2018 | 93 | 0.71 | Why? |
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2017 | 6 | 0.71 | Why? |
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2018 | 106 | 0.70 | Why? |
| Cell Cycle Checkpoints | 1 | 2017 | 126 | 0.67 | Why? |
| Organ Sparing Treatments | 1 | 2017 | 91 | 0.67 | Why? |
| MicroRNAs | 3 | 2019 | 1787 | 0.67 | Why? |
| STAT3 Transcription Factor | 1 | 2019 | 268 | 0.65 | Why? |
| Carcinoma | 2 | 2017 | 256 | 0.65 | Why? |
| Antigens, Surface | 1 | 2017 | 181 | 0.64 | Why? |
| Estradiol | 1 | 2018 | 250 | 0.64 | Why? |
| Surgery, Computer-Assisted | 1 | 2018 | 183 | 0.62 | Why? |
| Central Venous Catheters | 1 | 2018 | 188 | 0.62 | Why? |
| Nerve Tissue Proteins | 1 | 2018 | 319 | 0.61 | Why? |
| Prostate-Specific Antigen | 1 | 2017 | 213 | 0.61 | Why? |
| Cell Proliferation | 4 | 2019 | 1973 | 0.61 | Why? |
| Prostate | 6 | 2018 | 283 | 0.60 | Why? |
| Sterilization | 1 | 2018 | 294 | 0.58 | Why? |
| Myosin Type II | 3 | 2018 | 6 | 0.57 | Why? |
| Catheter-Related Infections | 1 | 2018 | 381 | 0.54 | Why? |
| Genetic Predisposition to Disease | 3 | 2017 | 4027 | 0.53 | Why? |
| Genetic Association Studies | 1 | 2017 | 559 | 0.53 | Why? |
| Polymorphism, Genetic | 2 | 2017 | 1074 | 0.49 | Why? |
| Prostatectomy | 1 | 2017 | 485 | 0.48 | Why? |
| Renal Dialysis | 2 | 2020 | 4358 | 0.46 | Why? |
| Apoptosis | 4 | 2018 | 2335 | 0.46 | Why? |
| Reactive Oxygen Species | 1 | 2017 | 1136 | 0.45 | Why? |
| Alleles | 1 | 2017 | 1557 | 0.43 | Why? |
| Cross Infection | 4 | 2020 | 8675 | 0.43 | Why? |
| Muscle, Smooth | 3 | 2018 | 67 | 0.41 | Why? |
| Gene Regulatory Networks | 4 | 2019 | 820 | 0.40 | Why? |
| Coronavirus Infections | 22 | 2020 | 253789 | 0.40 | Why? |
| Chronic Pain | 1 | 2018 | 736 | 0.40 | Why? |
| Penis | 3 | 2019 | 101 | 0.39 | Why? |
| Pneumonia, Viral | 22 | 2020 | 243684 | 0.38 | Why? |
| Urologic Surgical Procedures, Male | 2 | 2019 | 36 | 0.38 | Why? |
| Mesenchymal Stem Cell Transplantation | 1 | 2020 | 1322 | 0.38 | Why? |
| Feedback, Physiological | 2 | 2019 | 56 | 0.37 | Why? |
| Male | 52 | 2021 | 367725 | 0.36 | Why? |
| Mice, Nude | 2 | 2019 | 340 | 0.36 | Why? |
| Xenograft Model Antitumor Assays | 2 | 2019 | 274 | 0.35 | Why? |
| Neoplasm Staging | 4 | 2019 | 1999 | 0.34 | Why? |
| Environmental Monitoring | 1 | 2020 | 3143 | 0.34 | Why? |
| Endoscopy | 1 | 2018 | 1564 | 0.34 | Why? |
| Gene Expression | 1 | 2018 | 3332 | 0.33 | Why? |
| Urinary Bladder | 2 | 2018 | 170 | 0.33 | Why? |
| Bacteremia | 1 | 2018 | 1372 | 0.33 | Why? |
| Antibodies, Viral | 8 | 2021 | 51949 | 0.33 | Why? |
| Betacoronavirus | 21 | 2020 | 204454 | 0.32 | Why? |
| Membrane Proteins | 1 | 2017 | 1733 | 0.32 | Why? |
| Neoplasm Grading | 2 | 2018 | 400 | 0.32 | Why? |
| Cell Line, Tumor | 4 | 2019 | 3608 | 0.32 | Why? |
| Muscle Contraction | 4 | 2018 | 60 | 0.32 | Why? |
| Signal Transduction | 5 | 2019 | 7207 | 0.31 | Why? |
| Publication Bias | 2 | 2017 | 241 | 0.31 | Why? |
| Mass Screening | 3 | 2020 | 8005 | 0.31 | Why? |
| Gene Expression Regulation, Neoplastic | 5 | 2018 | 1014 | 0.31 | Why? |
| Immunoglobulin G | 7 | 2021 | 21571 | 0.30 | Why? |
| Disease Progression | 7 | 2020 | 13580 | 0.30 | Why? |
| Epithelial-Mesenchymal Transition | 2 | 2019 | 242 | 0.30 | Why? |
| Humans | 68 | 2021 | 930598 | 0.29 | Why? |
| Occupational Diseases | 1 | 2020 | 2787 | 0.28 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2017 | 3607 | 0.26 | Why? |
| China | 16 | 2021 | 50654 | 0.26 | Why? |
| Down-Regulation | 3 | 2019 | 1416 | 0.26 | Why? |
| TRPM Cation Channels | 2 | 2017 | 25 | 0.25 | Why? |
| Protein Isoforms | 3 | 2018 | 347 | 0.24 | Why? |
| Testosterone | 2 | 2018 | 596 | 0.24 | Why? |
| Female | 32 | 2021 | 380317 | 0.24 | Why? |
| Aging | 1 | 2018 | 3581 | 0.23 | Why? |
| Transcriptome | 4 | 2019 | 3466 | 0.23 | Why? |
| Protein Interaction Maps | 2 | 2019 | 1333 | 0.21 | Why? |
| Kaplan-Meier Estimate | 3 | 2019 | 4260 | 0.21 | Why? |
| Health Personnel | 3 | 2020 | 29646 | 0.21 | Why? |
| Gene Ontology | 2 | 2019 | 391 | 0.20 | Why? |
| Hospitals | 1 | 2020 | 11793 | 0.20 | Why? |
| Recurrence | 2 | 2020 | 3675 | 0.20 | Why? |
| Cyclin A2 | 1 | 2019 | 1 | 0.20 | Why? |
| Gene Knockdown Techniques | 2 | 2017 | 347 | 0.20 | Why? |
| Transaminases | 1 | 2020 | 152 | 0.20 | Why? |
| Middle Aged | 26 | 2021 | 270681 | 0.20 | Why? |
| Chromosomal Proteins, Non-Histone | 1 | 2019 | 33 | 0.19 | Why? |
| Microfilament Proteins | 1 | 2019 | 45 | 0.19 | Why? |
| Tomography, X-Ray Computed | 4 | 2020 | 25144 | 0.19 | Why? |
| Hyaluronan Receptors | 1 | 2019 | 61 | 0.19 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2018 | 10649 | 0.19 | Why? |
| Pandemics | 21 | 2020 | 389249 | 0.19 | Why? |
| Somatomedins | 1 | 2018 | 7 | 0.19 | Why? |
| Neoplasm Invasiveness | 2 | 2018 | 582 | 0.18 | Why? |
| Interleukin-6 | 1 | 2017 | 7522 | 0.18 | Why? |
| Smooth Muscle Myosins | 1 | 2017 | 2 | 0.18 | Why? |
| Heterografts | 1 | 2019 | 203 | 0.18 | Why? |
| Receptors, Lysosphingolipid | 1 | 2017 | 25 | 0.18 | Why? |
| Anilides | 1 | 2019 | 105 | 0.18 | Why? |
| Extracellular Matrix Proteins | 1 | 2019 | 95 | 0.18 | Why? |
| Ezetimibe | 1 | 2018 | 50 | 0.18 | Why? |
| Blood-Borne Pathogens | 1 | 2018 | 54 | 0.18 | Why? |
| Simvastatin | 1 | 2018 | 63 | 0.18 | Why? |
| Umbilical Cord | 1 | 2020 | 358 | 0.18 | Why? |
| Oxidative Phosphorylation | 1 | 2017 | 120 | 0.18 | Why? |
| Mice, Inbred NOD | 1 | 2017 | 134 | 0.18 | Why? |
| Mice, Inbred BALB C | 2 | 2019 | 5814 | 0.18 | Why? |
| RNAi Therapeutics | 1 | 2017 | 35 | 0.18 | Why? |
| Parity | 1 | 2018 | 122 | 0.17 | Why? |
| Penile Erection | 1 | 2017 | 58 | 0.17 | Why? |
| Mice, SCID | 1 | 2017 | 225 | 0.17 | Why? |
| Disease Transmission, Infectious | 2 | 2020 | 9044 | 0.17 | Why? |
| Heterocyclic Compounds, 4 or More Rings | 1 | 2018 | 139 | 0.17 | Why? |
| Survival Rate | 4 | 2020 | 9206 | 0.17 | Why? |
| Masks | 1 | 2020 | 8528 | 0.17 | Why? |
| Insulin-Like Growth Factor I | 1 | 2018 | 119 | 0.17 | Why? |
| Lysophospholipids | 1 | 2017 | 74 | 0.17 | Why? |
| Urinary Incontinence | 1 | 2018 | 148 | 0.17 | Why? |
| Certification | 1 | 2020 | 261 | 0.17 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.16 | Why? |
| Carcinogenesis | 1 | 2019 | 236 | 0.16 | Why? |
| Sphingosine | 1 | 2017 | 101 | 0.16 | Why? |
| Adult | 21 | 2021 | 244371 | 0.16 | Why? |
| Doxorubicin | 1 | 2019 | 313 | 0.16 | Why? |
| Prognosis | 6 | 2021 | 32490 | 0.16 | Why? |
| Suture Techniques | 1 | 2018 | 138 | 0.16 | Why? |
| Nucleic Acids | 1 | 2021 | 435 | 0.16 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.16 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.16 | Why? |
| Practice Guidelines as Topic | 2 | 2020 | 15421 | 0.16 | Why? |
| Neoplasms | 4 | 2021 | 17251 | 0.15 | Why? |
| Oseltamivir | 1 | 2020 | 583 | 0.15 | Why? |
| Chemoprevention | 1 | 2020 | 585 | 0.15 | Why? |
| Tea | 1 | 2017 | 126 | 0.15 | Why? |
| Neoplasm Metastasis | 1 | 2019 | 682 | 0.15 | Why? |
| Odds Ratio | 2 | 2017 | 5861 | 0.15 | Why? |
| Systems Biology | 1 | 2017 | 320 | 0.14 | Why? |
| Promoter Regions, Genetic | 1 | 2019 | 823 | 0.14 | Why? |
| Risk Factors | 11 | 2021 | 71621 | 0.14 | Why? |
| Rats, Sprague-Dawley | 4 | 2018 | 987 | 0.14 | Why? |
| Treatment Outcome | 8 | 2020 | 51732 | 0.14 | Why? |
| Family Health | 1 | 2020 | 731 | 0.14 | Why? |
| Survival Analysis | 2 | 2018 | 7592 | 0.14 | Why? |
| Retroperitoneal Space | 1 | 2014 | 68 | 0.14 | Why? |
| Immunoglobulin M | 3 | 2021 | 9091 | 0.14 | Why? |
| RNA Interference | 1 | 2017 | 534 | 0.14 | Why? |
| Ureter | 1 | 2014 | 59 | 0.14 | Why? |
| Infection Control | 2 | 2020 | 23131 | 0.13 | Why? |
| Sarcopenia | 1 | 2019 | 422 | 0.13 | Why? |
| Disease-Free Survival | 1 | 2019 | 1654 | 0.13 | Why? |
| DNA Methylation | 1 | 2019 | 688 | 0.13 | Why? |
| Catechin | 1 | 2017 | 244 | 0.13 | Why? |
| Hematology | 1 | 2020 | 649 | 0.13 | Why? |
| Imaging, Three-Dimensional | 1 | 2018 | 680 | 0.13 | Why? |
| Transurethral Resection of Prostate | 1 | 2012 | 20 | 0.12 | Why? |
| Computational Biology | 2 | 2019 | 4514 | 0.12 | Why? |
| Safety | 1 | 2020 | 1583 | 0.12 | Why? |
| Pharynx | 1 | 2020 | 1544 | 0.12 | Why? |
| ABO Blood-Group System | 1 | 2021 | 995 | 0.12 | Why? |
| Printing, Three-Dimensional | 1 | 2018 | 624 | 0.12 | Why? |
| Tuberculosis, Multidrug-Resistant | 1 | 2017 | 433 | 0.12 | Why? |
| Aged | 17 | 2021 | 215776 | 0.11 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.11 | Why? |
| Anti-Infective Agents, Local | 1 | 2018 | 520 | 0.11 | Why? |
| Spike Glycoprotein, Coronavirus | 3 | 2021 | 37182 | 0.11 | Why? |
| Personal Protective Equipment | 3 | 2020 | 15978 | 0.11 | Why? |
| Equipment Contamination | 1 | 2020 | 1308 | 0.11 | Why? |
| Feasibility Studies | 1 | 2020 | 3467 | 0.11 | Why? |
| Age Distribution | 1 | 2020 | 3567 | 0.11 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.11 | Why? |
| Antitubercular Agents | 1 | 2017 | 775 | 0.11 | Why? |
| Observational Studies as Topic | 1 | 2017 | 1887 | 0.10 | Why? |
| Retrospective Studies | 9 | 2021 | 105322 | 0.10 | Why? |
| Methylprednisolone | 1 | 2020 | 2107 | 0.09 | Why? |
| Animals | 7 | 2019 | 78931 | 0.09 | Why? |
| Pilot Projects | 1 | 2020 | 5182 | 0.09 | Why? |
| Antimalarials | 1 | 2021 | 2505 | 0.09 | Why? |
| Phenylephrine | 2 | 2017 | 20 | 0.09 | Why? |
| Cities | 1 | 2020 | 4937 | 0.09 | Why? |
| Hypertension | 2 | 2020 | 8895 | 0.08 | Why? |
| Antibody Formation | 1 | 2020 | 4038 | 0.08 | Why? |
| Disinfection | 1 | 2020 | 2912 | 0.08 | Why? |
| Real-Time Polymerase Chain Reaction | 3 | 2020 | 11367 | 0.08 | Why? |
| Urologic Diseases | 1 | 2014 | 860 | 0.08 | Why? |
| Diabetes Complications | 1 | 2018 | 2358 | 0.07 | Why? |
| Genotype | 1 | 2017 | 4697 | 0.07 | Why? |
| Clinical Laboratory Techniques | 3 | 2020 | 23402 | 0.07 | Why? |
| Seroepidemiologic Studies | 1 | 2020 | 10017 | 0.07 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2020 | 3892 | 0.06 | Why? |
| Prevalence | 3 | 2020 | 25773 | 0.06 | Why? |
| Laparoscopy | 1 | 2014 | 1532 | 0.06 | Why? |
| Surveys and Questionnaires | 2 | 2020 | 43792 | 0.06 | Why? |
| Cross-Sectional Studies | 2 | 2020 | 53120 | 0.06 | Why? |
| Tertiary Care Centers | 1 | 2020 | 8248 | 0.06 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 5277 | 0.06 | Why? |
| Kidney Failure, Chronic | 1 | 2018 | 3222 | 0.06 | Why? |
| Young Adult | 7 | 2021 | 93724 | 0.06 | Why? |
| Lung Neoplasms | 1 | 2019 | 3228 | 0.06 | Why? |
| Occupational Exposure | 1 | 2020 | 4742 | 0.06 | Why? |
| Asymptomatic Infections | 1 | 2020 | 7218 | 0.06 | Why? |
| Sensitivity and Specificity | 2 | 2020 | 22971 | 0.05 | Why? |
| Seroconversion | 2 | 2021 | 2515 | 0.05 | Why? |
| Rats | 2 | 2018 | 2764 | 0.05 | Why? |
| Breast Neoplasms | 1 | 2018 | 3633 | 0.05 | Why? |
| Convalescence | 2 | 2021 | 2829 | 0.05 | Why? |
| Antibodies, Neutralizing | 3 | 2021 | 25288 | 0.05 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.05 | Why? |
| Larynx | 1 | 2020 | 126 | 0.05 | Why? |
| Double-Blind Method | 2 | 2021 | 5988 | 0.05 | Why? |
| Serum Amyloid A Protein | 1 | 2020 | 211 | 0.05 | Why? |
| Mice | 1 | 2019 | 21357 | 0.05 | Why? |
| Viral Vaccines | 1 | 2020 | 7560 | 0.05 | Why? |
| Cephalosporins | 1 | 2021 | 250 | 0.05 | Why? |
| Medical Illustration | 1 | 2018 | 35 | 0.05 | Why? |
| RNA, Viral | 3 | 2021 | 32276 | 0.05 | Why? |
| Blood Sedimentation | 1 | 2020 | 508 | 0.05 | Why? |
| Carbachol | 1 | 2017 | 5 | 0.05 | Why? |
| Injections, Intramuscular | 1 | 2021 | 800 | 0.05 | Why? |
| Nitroprusside | 1 | 2017 | 18 | 0.05 | Why? |
| Adolescent | 5 | 2021 | 86841 | 0.04 | Why? |
| Potassium Chloride | 1 | 2017 | 24 | 0.04 | Why? |
| Orchiectomy | 1 | 2017 | 63 | 0.04 | Why? |
| Immunity, Cellular | 2 | 2021 | 3614 | 0.04 | Why? |
| Vital Signs | 1 | 2020 | 257 | 0.04 | Why? |
| Organ Culture Techniques | 1 | 2017 | 119 | 0.04 | Why? |
| Genome, Viral | 1 | 2020 | 13157 | 0.04 | Why? |
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2017 | 49 | 0.04 | Why? |
| Tissue Array Analysis | 1 | 2017 | 75 | 0.04 | Why? |
| Cystectomy | 1 | 2019 | 218 | 0.04 | Why? |
| Organophosphates | 1 | 2017 | 66 | 0.04 | Why? |
| Cadherins | 1 | 2017 | 145 | 0.04 | Why? |
| Evidence-Based Medicine | 2 | 2020 | 3228 | 0.04 | Why? |
| Organ Size | 1 | 2017 | 384 | 0.04 | Why? |
| Stress, Psychological | 1 | 2020 | 10231 | 0.04 | Why? |
| Myocytes, Smooth Muscle | 1 | 2017 | 127 | 0.04 | Why? |
| Calcium Signaling | 1 | 2017 | 133 | 0.04 | Why? |
| Operative Time | 1 | 2018 | 450 | 0.04 | Why? |
| Anticholesteremic Agents | 1 | 2018 | 186 | 0.04 | Why? |
| Hospital Mortality | 1 | 2020 | 22087 | 0.04 | Why? |
| Photography | 1 | 2018 | 255 | 0.04 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.04 | Why? |
| Cardiovascular Diseases | 1 | 2020 | 11497 | 0.04 | Why? |
| In Vitro Techniques | 1 | 2018 | 1027 | 0.04 | Why? |
| Fluid Therapy | 1 | 2020 | 628 | 0.04 | Why? |
| Administration, Inhalation | 1 | 2021 | 1647 | 0.04 | Why? |
| Child | 3 | 2019 | 70012 | 0.04 | Why? |
| Troponin T | 1 | 2020 | 771 | 0.03 | Why? |
| Nursing Care | 1 | 2020 | 328 | 0.03 | Why? |
| Steroids | 1 | 2020 | 904 | 0.03 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.03 | Why? |
| Lymphocyte Subsets | 1 | 2021 | 987 | 0.03 | Why? |
| Adenoviridae | 1 | 2020 | 1151 | 0.03 | Why? |
| Cholesterol, LDL | 1 | 2018 | 499 | 0.03 | Why? |
| Molecular Epidemiology | 1 | 2020 | 1638 | 0.03 | Why? |
| Immunization Schedule | 1 | 2021 | 1305 | 0.03 | Why? |
| Immunization, Secondary | 1 | 2021 | 1649 | 0.03 | Why? |
| Area Under Curve | 1 | 2020 | 2564 | 0.03 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.03 | Why? |
| Genetic Vectors | 1 | 2020 | 1600 | 0.03 | Why? |
| Organ Specificity | 1 | 2017 | 1070 | 0.03 | Why? |
| Natriuretic Peptide, Brain | 1 | 2020 | 1215 | 0.03 | Why? |
| Prospective Studies | 4 | 2019 | 43301 | 0.03 | Why? |
| Antiviral Agents | 3 | 2020 | 41703 | 0.03 | Why? |
| Testis | 1 | 2017 | 566 | 0.03 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.03 | Why? |
| Azetidines | 1 | 2018 | 722 | 0.03 | Why? |
| Antigens, CD | 1 | 2017 | 984 | 0.03 | Why? |
| Pyridines | 1 | 2017 | 680 | 0.03 | Why? |
| Treatment Failure | 1 | 2017 | 2106 | 0.03 | Why? |
| Leukocyte Count | 1 | 2020 | 3178 | 0.03 | Why? |
| Hand Disinfection | 1 | 2020 | 1671 | 0.03 | Why? |
| Multivariate Analysis | 1 | 2021 | 5440 | 0.02 | Why? |
| Phytotherapy | 1 | 2017 | 743 | 0.02 | Why? |
| Peptide Fragments | 1 | 2020 | 2075 | 0.02 | Why? |
| RNA, Messenger | 2 | 2018 | 5131 | 0.02 | Why? |
| Immunoglobulins, Intravenous | 1 | 2020 | 2705 | 0.02 | Why? |
| Disease Susceptibility | 1 | 2021 | 4002 | 0.02 | Why? |
| Risk | 1 | 2020 | 5288 | 0.02 | Why? |
| Pyrazoles | 1 | 2017 | 1791 | 0.02 | Why? |
| Dietary Supplements | 1 | 2019 | 2251 | 0.02 | Why? |
| Serologic Tests | 1 | 2021 | 4359 | 0.02 | Why? |
| Immunity, Humoral | 1 | 2021 | 4849 | 0.02 | Why? |
| ROC Curve | 1 | 2018 | 6024 | 0.02 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 1510 | 0.02 | Why? |
| Chloroquine | 1 | 2021 | 3152 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2018 | 6543 | 0.02 | Why? |
| Immunogenicity, Vaccine | 1 | 2021 | 4624 | 0.02 | Why? |
| Amino Acid Sequence | 1 | 2017 | 6049 | 0.02 | Why? |
| Logistic Models | 1 | 2020 | 9089 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2020 | 9537 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2020 | 7220 | 0.02 | Why? |
| Epithelial Cells | 1 | 2017 | 3508 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2017 | 4020 | 0.02 | Why? |
| Patient Discharge | 1 | 2020 | 5696 | 0.02 | Why? |
| Antineoplastic Agents | 1 | 2020 | 3550 | 0.02 | Why? |
| Drugs, Chinese Herbal | 1 | 2020 | 2760 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.02 | Why? |
| Inpatients | 1 | 2020 | 5161 | 0.02 | Why? |
| Fever | 1 | 2021 | 7795 | 0.02 | Why? |
| Cell Line | 1 | 2018 | 12040 | 0.02 | Why? |
| T-Lymphocytes | 1 | 2020 | 6670 | 0.02 | Why? |
| Research Design | 1 | 2018 | 5830 | 0.01 | Why? |
| Percutaneous Coronary Intervention | 1 | 2018 | 3646 | 0.01 | Why? |
| Lung | 2 | 2020 | 31049 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2017 | 11304 | 0.01 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.01 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.01 | Why? |
| Cytokines | 1 | 2021 | 15010 | 0.01 | Why? |
| Incidence | 1 | 2020 | 25622 | 0.01 | Why? |
| Anti-Bacterial Agents | 1 | 2020 | 10083 | 0.01 | Why? |
| Biomarkers | 1 | 2020 | 23361 | 0.01 | Why? |
| Hydroxychloroquine | 1 | 2021 | 12447 | 0.01 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.01 | Why? |
| Diabetes Mellitus | 1 | 2018 | 8207 | 0.01 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.01 | Why? |
| Child, Preschool | 1 | 2018 | 36283 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.01 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.01 | Why? |